IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt FacilityBusiness Wire • 12/20/21
Role of B Cells Induced by IMV's Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO CongressBusiness Wire • 12/02/21
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast CancerBusiness Wire • 11/30/21
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual MeetingBusiness Wire • 11/09/21
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021Business Wire • 11/04/21
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 10/07/21
Potential Response Predictors to IMV's Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual MeetingBusiness Wire • 10/01/21
IMV's DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 09/30/21
IMV's Shares Jump As Ovarian Cancer Candidate Shows Overall Survival Rate Of 44.9%Benzinga • 08/10/21
IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian CancerBusiness Wire • 08/10/21
IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021Business Wire • 08/02/21